Registry of Lobbyists
Subject matters | Details | Categories |
---|---|---|
Budget,
Health,
Research and Development
|
Advocate for increased government funding for research related to arthritis and to support patient oriented research. Government support for health charities.
|
Grant, Contribution or Other Financial Benefit
|
Budget,
Health,
Research and Development
|
Discussion with government officials about national pharmacare (Bill C-64) and timely access to treatment for people living with arthritis.
|
Legislative Proposal, Bill or Resolution,
Policies or Program
|
Health
|
Discussions with government about support for people living with arthritis
|
Policies or Program
|
Health
|
Discussions with government officials with respect to policy and regulation of medical cannabis.
|
Policies or Program,
Regulation
|
Budget,
Health,
Taxation and Finance
|
Excise Tax Act, specifically with respect to the application of sales tax on medical cannabis.
|
Policies or Program,
Regulation
|
Subject matters | Details | Categories |
---|---|---|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Advocacy for development of a coordinated national strategy for musculoskeletal conditions that will align strategic directions, exchange best practices and integration of prevention, detection and management systems across Canada
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Canada Pension Plan, specifically the term "severe and prolonged" in s. 42 to broaden its application to more Canadians.
|
Regulation
|
Budget,
Health,
Research and Development
|
Communication with federal government officials with respect to promoting research and federal-provincial coordination in best practices for arthritis patient care
|
Policies or Program
|
Health
|
Discuss with government about support for people living with arthritis.
|
Policies or Program
|
Budget,
Health,
Research and Development
|
Discussion with government officials about national pharmacare and timely access to treatment for people living with arthritis.
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Discussions with government officials with respect to the legalization and regulation of marijuana as it relates to medical cannabis policy
|
Legislative Proposal, Bill or Resolution
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Employment Insurance Act, specifically with respect to episodic disabilities and/or caregivers
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Engagement with the Advisory Committee on the Implementation of National Pharmacare and its Secretariat on issues related to medicines for chronic diseases, such as arthritis
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Excise Tax Act, specifically with respect to the application of sales tax on medical cannabis
|
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drugs Act and Regulations, specifically with respect to the special access programme for patients living with arthritis
|
Legislative Proposal, Bill or Resolution,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Funding from the federal government for research related to arthritis and to support patient oriented research
|
Grant, Contribution or Other Financial Benefit,
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Health Canada's office of pharmaceutical management strategies, specifically with respect to Health Canada's role in supporting and directing federal, national and inter-jurisdictional pharmaceutical policy
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patented Medicine Prices Review Board, specifically with respect to the regulation of pricing of patented drug products
|
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Promoting workplace productivity and wellness initiatives for musculoskeletal health
|
Policies or Program
|
Communication techniques that have been used or are expected to be used in the course of the undertaking: